TRVI earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -53.88. Updated 2026-07-23.
Trevi Therapeutics (TRVI) Research Hub
Trevi Therapeutics (TRVI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.9 USD (-4.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -53.88, market cap 2.46B. This hub links to the full technical, earnings and options research available for TRVI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.9 USD (-4.45%) |
| 52-week range | 14.38 USD – 20.15 USD |
| Trend regime | Range |
| 14-day RSI | 28.3 (Oversold) |
| Trailing P/E | -53.88 |
| Market cap | 2.46B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for TRVI
Covered Call on TRVI: how it works, illustrative setup around the real 15.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TRVI: how it works, illustrative setup around the real 15.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TRVI: how it works, illustrative setup around the real 15.9 USD price, max profit/loss, breakeven and when to use it. Educational.
TRVI technical analysis: range, last 15.9 USD, RSI 28.3, 52w range 14.38 USD–20.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TRVI in?
Trevi Therapeutics (TRVI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TRVI in an uptrend or downtrend?
As of 2026-09-11, TRVI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TRVI's trailing P/E ratio?
TRVI's trailing P/E is -53.88, with a market cap of 2.46B. See the earnings research page for full valuation detail.
When does TRVI next report earnings?
TRVI is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.11 USD.